March 13th 2023
The final analysis of the phase 2/3 CCTG IND.227/KEYNOTE-483 trial identifies a statistically significant survival benefit with pembrolizumab and chemotherapy vs chemotherapy alone in the first-line setting for patients with unresectable advanced or metastatic malignant pleural mesothelioma.
Changes to 2021 USPSTF Lung Cancer Screening Guidelines Broaden Eligibility, Reduce Racial DisparitiesFebruary 4th 2022
The 2021 United States Preventive Services Task Force lung cancer screening criteria changes successfully reduced racial disparities in eligibility by broadening screening eligibility criteria.
Low-Dose CT Screenings Associated With Lung Cancer Overdiagnosis in Nonsmoking Asian WomenJanuary 27th 2022
Investigators believe that low-dose CT screenings should only be offered to heavy smokers after identifying an association between the diagnostic and an overdiagnosis in nonsmoking Asian women.
Blood-Based Biomarker Panel Plus Personalized Risk Model Improved Risk Assessment for Lung Cancer ScreeningsJanuary 17th 2022
Investigators reported that combining a blood-based biomarker panel with PLCOm2012 resulted in a significant improvement in risk assessment for lung cancer screenings.
Recap: Experts Discuss NRG1 Fusions as Key Oncogenic Drivers for Certain Patients With Lung CancerDecember 30th 2021
D. Ross Camidge, MD, PhD, and Alexander I. Spira, MD, PhD, discussed the use of NRG1 fusions as being a driver for patients with lung cancer.
Hossein Borghaei, DO, MS, Offers His Advice on Staying Up to Date With Lung Cancer ResearchNovember 25th 2021
CancerNetwork® sat down with Hossein Borghaei, DO, MS, to talk about keeping track of conference and journal updates to help build and maintain knowledge around lung cancer.
Lung Cancer Screenings Remained Stable in US Throughout the COVID-19 Pandemic, With Some States Seeing improvementsNovember 21st 2021
Most states in the United States had stable rates of lung cancer screenings during the COVID-19 pandemic, with some even experiencing significant improvements.
Expert Commentary on the Product Profile of TepotinibNovember 14th 2021
In an interview with ONCOLOGY®, David Hughes PharmD, BCOP, and Jessica Freydman, PharmD, offers a comprehensive review of real-world treatment considerations of tepotinib as therapy for patients with metastatic non–small cell lung cancer that have MET exon14 skipping mutations.
Neuronal Autoantibodies May be Associated With Cognitive Impairment in Lung CancerOctober 31st 2021
The presence of neuronal autoantibodies in patients with lung cancer, specifically small cell lung cancer and non–small cell lung cancer, appears to be associated with cognitive impairment.
NRG1 Fusion-Driven Lung Cancer: Future Directions in CareOctober 29th 2021
Experts Alexander Spira, MD, PhD, FACP, and D. Ross Camidge, MD, PhD, highlight the importance of global registries before sharing their closing thoughts on NRG1 fusions and the future treatment landscape of lung cancer.
Edward B. Garon, MD, Discusses Outcomes in NSCLC With Dato-DXd From TROPION-PanTumor01October 14th 2021
CancerNetwork® sat down with Edward B. Garon, MD, at the 2021 World Conference on Lung Cancer to talk about key findings with datopotamab deruxtecan therapy in patients with non–small cell lung cancer and other ongoing trials.
Alexander Spira, MD, PhD, FACP, Discusses Impacts of COVID-19 at Individual Treatment FacilitiesSeptember 25th 2021
CancerNetwork® sat down with Alexander Spira, MD, PhD, FACP, at the 2021 World Conference on Lung Cancer to talk about COVID-19 and immediate changes that took place during the pandemic.
Nivolumab Plus Ipilimumab Demonstrate Continued Survival Benefit in All Subgroups in Unresectable Malignant Pleural MesotheliomaSeptember 18th 2021
Findings from the phase 3 CheckMate 743 trial indicated that patients with unresectable malignant pleural mesothelioma derived a continued overall survival benefit after being treated with nivolumab and ipilimumab.
Alexander Spira, MD, PhD, FACP, Discusses Biomarker-Guided Treatment in Lung Cancer at 2021 WCLCSeptember 10th 2021
CancerNetwork® sat down with Alexander Spira, MD, PhD, FACP, at the 2021 World Conference on Lung Cancer to talk about KRAS as a therapy biomarker in lung cancer.
Study Confirms Heightened Hospitalizations, Mortality With COVID-19 in Patients With Malignant Pleural MesotheliomaSeptember 9th 2021
In the early days of the COVID-19 pandemic, patients with malignant pleural mesothelioma were more likely to be hospitalized or die from COVID-19 versus the overall population.
Potential Translational Relevance of Preclinical Findings With SeribantumabAugust 26th 2021
Thoracic oncologists discuss key takeaways and potential translational relevance of seribantumab based on a recent publication by Igor Odintsov, MD, and colleagues.